USA – Biosimilar labeling guidance suggests cutting interchangeability details from labels
In new draft guidance on biosimilar labeling, the US Food and Drug Administration (FDA) recommends removing details about interchangeability from the labels of these products, suggesting that the designation is confusing to prescribers and patients.
The FDA guidance can be found on its website.
More information on RIS.World.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (12 mars 2024). USA – Biosimilar labeling guidance suggests cutting interchangeability details from labels. ELSIBI. Consulté le 18 janvier 2026 à l’adresse https://doi.org/10.58079/w0a3





